ECSP13012984A - Compuestos heterocíclicos como inhibidores de cinasas - Google Patents

Compuestos heterocíclicos como inhibidores de cinasas

Info

Publication number
ECSP13012984A
ECSP13012984A ECSP13012984A ECSP13012984A EC SP13012984 A ECSP13012984 A EC SP13012984A EC SP13012984 A ECSP13012984 A EC SP13012984A EC SP13012984 A ECSP13012984 A EC SP13012984A
Authority
EC
Ecuador
Prior art keywords
diseases
kinases
kinase
disease
inhibitors
Prior art date
Application number
Other languages
English (en)
Inventor
Michael Thormann
Andreas Treml
Michael Almstetter
Roland Koestler
Nasser Yehia
Original Assignee
Origenis Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Origenis Gmbh filed Critical Origenis Gmbh
Publication of ECSP13012984A publication Critical patent/ECSP13012984A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La presente invención se refiere a nuevos compuestos de fórmula (I), que son capaces de inhibir una o más cinasas, especialmente SYK (tirosina cinasa de bazo), LRRK2 (cinasa 2 de repetición rica en leucina) y/o MYLK (cinasa de las cadenas ligeras de miosina) o sus mutantes. Los compuestos encuentran aplicaciones en el tratamiento de una variedad de enfermedades. Estas enfermedades incluyen enfermedades autoinmunitarias, enfermedades inflamatorias, enfermedades óseas, enfermedades metabólicas, enfermedades neurológicas y neurodegenerativas, cáncer, enfermedades cardiovasculares, alergias, asma, enfermedad de Alzheimer, enfermedad de Parkinson, enfermedades de la piel, enfermedades oculares, enfermedades infecciosas y enfermedades relacionadas con hormonas.
ECSP13012984 2011-04-21 2013-10-21 Compuestos heterocíclicos como inhibidores de cinasas ECSP13012984A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161517581P 2011-04-21 2011-04-21

Publications (1)

Publication Number Publication Date
ECSP13012984A true ECSP13012984A (es) 2014-09-30

Family

ID=46001141

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012984 ECSP13012984A (es) 2011-04-21 2013-10-21 Compuestos heterocíclicos como inhibidores de cinasas

Country Status (25)

Country Link
US (1) US9499535B2 (es)
EP (1) EP2699572B1 (es)
JP (1) JP6278406B2 (es)
KR (1) KR101649610B1 (es)
CN (1) CN103717597B (es)
AP (1) AP2013007252A0 (es)
AU (1) AU2012244549B2 (es)
BR (1) BR112013026744B1 (es)
CA (1) CA2831680C (es)
CL (1) CL2013003052A1 (es)
CO (1) CO6831983A2 (es)
CR (1) CR20130537A (es)
CU (1) CU20130144A7 (es)
EA (1) EA034193B1 (es)
EC (1) ECSP13012984A (es)
GT (1) GT201300259A (es)
HK (1) HK1192247A1 (es)
IL (1) IL228967B (es)
MA (1) MA35123B1 (es)
MX (1) MX365784B (es)
PE (1) PE20140927A1 (es)
SG (1) SG194216A1 (es)
TN (1) TN2013000422A1 (es)
TW (1) TWI557121B (es)
WO (1) WO2012143143A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2831680C (en) 2011-04-21 2020-04-21 Origenis Gmbh Heterocyclic compounds as kinase inhibitors
PE20141066A1 (es) 2011-04-21 2014-09-05 Gilead Sciences Inc Compuestos de benzotiazol
WO2013103738A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. Napthalene acetic acid derivatives against hiv infection
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
AR090650A1 (es) 2012-04-12 2014-11-26 Alcon Res Ltd Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo
JP6189948B2 (ja) 2012-06-29 2017-08-30 ファイザー・インク ＬＲＲＫ２阻害薬としての新規な４−（置換アミノ）−７Ｈ−ピロロ［２，３−ｄ］ピリミジン
CN112587658A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
US10000482B2 (en) * 2012-10-19 2018-06-19 Origenis Gmbh Kinase inhibitors
CN105143232A (zh) * 2013-03-15 2015-12-09 益普生制药股份有限公司 大环的lrrk2激酶抑制剂
WO2015026683A1 (en) * 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2015082887A2 (en) * 2013-12-02 2015-06-11 Bergenbio As Use of kinase inhibitors
CA2933767C (en) 2013-12-17 2018-11-06 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
AU2015205756A1 (en) 2014-01-10 2016-07-21 Birdie Biopharmaceuticals Inc. Compounds and compositions for treating EGFR expressing tumors
CN105440135A (zh) 2014-09-01 2016-03-30 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
WO2016004876A1 (en) 2014-07-09 2016-01-14 Shanghai Birdie Biotech, Inc. Anti-pd-l1 combinations for treating tumors
EP3166637B1 (en) 2014-07-10 2020-01-29 The J. David Gladstone Institutes Compositions and methods for treating dengue virus infection
JP6607962B2 (ja) * 2015-05-26 2019-11-20 カオシュン メディカル ユニバーシティー β−グルクロニダーゼの阻害のためのピラゾロ［４，３−ｃ］キノリン誘導体
KR102161364B1 (ko) 2015-09-14 2020-09-29 화이자 인코포레이티드 LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체
CN105664178B (zh) * 2015-09-24 2019-08-20 洪健 Syk作为肝纤维化/硬化治疗靶点的应用
CN115554406A (zh) 2016-01-07 2023-01-03 博笛生物科技有限公司 用于治疗肿瘤的抗-cd20组合
CN106943598A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-her2组合
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-egfr组合
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
PE20191474A1 (es) 2016-12-20 2019-10-16 Astrazeneca Ab Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
EP3595658A4 (en) * 2017-03-16 2020-11-25 Celgene CAR LLC FORMS AND COMPOSITIONS OF A MK2 INHIBITOR
CN108794467A (zh) * 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
BR112019027025A2 (pt) 2017-06-23 2020-06-30 Birdie Biopharmaceuticals, Inc. composições farmacêuticas
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
SI3723807T1 (sl) 2017-12-14 2022-01-31 H. Lundbeck A/S Kombinirana zdravljenja, ki obsegajo dajanje 1H-pirazolo(4,3-b)piridinov
CN117447475A (zh) 2017-12-20 2024-01-26 H.隆德贝克有限公司 作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶
JP2020132986A (ja) * 2019-02-25 2020-08-31 東京エレクトロン株式会社 成膜用組成物および成膜方法
CN116854706A (zh) * 2019-04-18 2023-10-10 四川科伦博泰生物医药股份有限公司 稠环化合物、其制备方法及用途
CN115103844A (zh) * 2019-09-13 2022-09-23 原真股份有限公司 用于治疗例如自身免疫性疾病的作为lrrk2、nuak1和/或tyk2激酶调节剂的1,4-二氢苯并[d]吡唑并[3,4-f][1,3]二氮杂卓衍生物和相关化合物
WO2021048620A1 (en) * 2019-09-13 2021-03-18 Origenis Gmbh 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as lrrk2, nuak1 and/or tyk2 kinase modulators for the treatment of e.g. autoimmune disease
EP4061374A1 (en) * 2019-11-20 2022-09-28 Yale University Compounds, compositions, and methods for treating ischemia-reperfusion injury and/or lung injury
WO2021207141A1 (en) * 2020-04-06 2021-10-14 The Regents Of The University Of Colorado, A Body Corporate METHODS OF USING NEUROKININ-1 RECEPTOR (NK-1R) ANTAGONISTS TO TREAT β-CORONAVIRUS INFECTION INCLUDING SARS-COV-2 INFECTION AND/OR COVID-19 DISEASE
CN113491700B (zh) * 2020-07-06 2023-03-28 军事科学院军事医学研究院军事兽医研究所 牛磺罗定在抗病毒中的应用
WO2022079250A1 (en) * 2020-10-16 2022-04-21 Merck Patent Gmbh Compounds for the treatment of viral infections
CN112138015B (zh) * 2020-10-22 2022-08-05 合肥博思科创医药科技有限公司 三苄糖苷在治疗微循环障碍引起的皮肤疾病中的应用
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
CN116808016A (zh) * 2022-01-13 2023-09-29 浙江中医药大学 依普黄酮在抑制炎症小体活化中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3068673D1 (en) 1979-06-21 1984-08-30 Ciba Geigy Ag Pyrazolo-quinolines, processes for their production, and pharmaceutical compositions containing them
US5360720A (en) 1993-10-08 1994-11-01 Alcon Laboratories, Inc. Method of preparing human conjunctival mast cells for mast cell stabilization assays
US5723608A (en) 1996-12-31 1998-03-03 Neurogen Corporation 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands
US6531475B1 (en) 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
GB0106661D0 (en) 2001-03-16 2001-05-09 Pfizer Ltd Pharmaceutically active compounds
US7544697B2 (en) * 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
WO2005079195A2 (en) * 2003-10-03 2005-09-01 3M Innovative Properties Company Pyrazolopyridines and analogs thereof
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
EP1863813A2 (en) 2005-04-01 2007-12-12 Coley Pharmaceutical Group, Inc. Pyrazolo[3,4-c]quinolines, pyrazolo[3,4-c]naphthyridines, analogs thereof, and methods
WO2006107851A1 (en) * 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
WO2008144253A1 (en) * 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
TW201612182A (en) * 2008-06-10 2016-04-01 Abbvie Inc Novel tricyclic compounds
US20110212053A1 (en) * 2008-06-19 2011-09-01 Dapeng Qian Phosphatidylinositol 3 kinase inhibitors
US20100120741A1 (en) 2008-09-10 2010-05-13 Kalypsys, Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease
JP2010143829A (ja) * 2008-12-16 2010-07-01 Dainippon Sumitomo Pharma Co Ltd 新規なイミダゾキノリン誘導体
PE20120506A1 (es) * 2009-03-19 2012-05-14 Medical Res Council Technology Derivados de pirazolopiridina como inhibidores de quinasas
CN102711476B (zh) 2009-12-01 2014-12-03 Abbvie公司 新的三环化合物
AU2010326030A1 (en) 2009-12-01 2012-06-07 Abbvie Inc. Novel tricyclic compounds
TW201204727A (en) 2010-03-10 2012-02-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
CA2831680C (en) 2011-04-21 2020-04-21 Origenis Gmbh Heterocyclic compounds as kinase inhibitors
US10000482B2 (en) 2012-10-19 2018-06-19 Origenis Gmbh Kinase inhibitors

Also Published As

Publication number Publication date
JP6278406B2 (ja) 2018-02-14
US9499535B2 (en) 2016-11-22
MX2013012295A (es) 2014-03-27
GT201300259A (es) 2016-07-07
CN103717597B (zh) 2017-07-04
AU2012244549A1 (en) 2013-10-31
KR20140009495A (ko) 2014-01-22
SG194216A1 (en) 2013-11-29
EP2699572B1 (en) 2016-08-10
AU2012244549B2 (en) 2017-04-20
TN2013000422A1 (en) 2015-03-30
EA034193B1 (ru) 2020-01-15
IL228967B (en) 2018-06-28
BR112013026744A2 (es) 2017-01-03
CL2013003052A1 (es) 2014-05-23
TWI557121B (zh) 2016-11-11
KR101649610B1 (ko) 2016-08-19
AP2013007252A0 (en) 2013-11-30
PE20140927A1 (es) 2014-08-24
MX365784B (es) 2019-05-28
CA2831680C (en) 2020-04-21
JP2014511884A (ja) 2014-05-19
TW201247666A (en) 2012-12-01
US20120329785A1 (en) 2012-12-27
CU20130144A7 (es) 2014-02-28
EP2699572A1 (en) 2014-02-26
CO6831983A2 (es) 2014-01-10
MA35123B1 (fr) 2014-05-02
CR20130537A (es) 2014-03-13
WO2012143143A1 (en) 2012-10-26
HK1192247A1 (zh) 2014-08-15
CN103717597A (zh) 2014-04-09
BR112013026744B1 (pt) 2022-05-17
EA201301183A1 (ru) 2014-04-30
CA2831680A1 (en) 2012-10-26
IL228967A0 (en) 2013-12-31

Similar Documents

Publication Publication Date Title
ECSP13012984A (es) Compuestos heterocíclicos como inhibidores de cinasas
ECSP13012982A (es) Pirazolo[4,3-d]pirimidinas útiles como inhibidores de cinasas
CL2017002483A1 (es) Compuestos heterocíclicos como inhibidores de lsd1
CL2012001073A1 (es) Compuestos derivados de pirido[4,3-d]pirimidin-5-ona, sus composiciones farmaceuticas y su uso como inhibidores de quinasa para tratar asma, epoc, colitis ulcerante, bronquitis, lupus, cancer de mamas, enfermedad de alzheimer, enfermedad de parkinson, osteoporosis, esclerosis multiple, diabetes, trastornos oculares, restenosis, enfermedades inflamatorias.
CU24275B1 (es) Derivados de cicloalquilo pirrolo [2,3-d] pirimidina-4-il amino útiles como inhibidores de quinasas janus relacionadas y composiciones farmacéuticas que contienen tales compuestos
CR20150255A (es) Derivados triciclicos fusionados de tiofeno como inhibidores de jak
CO6511283A2 (es) Primidinas sustituidas útiles en el tratamiento de enfermedades tales como cancer
UY32494A (es) Nuevas 2,4-diaminopirimidinas, sales farmacéuticas de las mismas, composiciones conteniéndolas y aplicaciones
UY32916A (es) Nuevas pirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones
UY32240A (es) Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
UY35898A (es) ?compuestos inhibidores de syk y composiciones que los comprenden?.
PE20150666A1 (es) Inhibidores de serina/treonina cinasa
CR20110610A (es) Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedades
GT201500054A (es) Moléculas de enlace a il-18
CR20120331A (es) Aminopirimidinas como inhibidores de syk
ECSP11011534A (es) 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octano- o heptano-nitrilo como inhibidores de jak
UY33587A (es) Nuevos compuestos como inhibidores de quinasas syk y jak
CO7350641A2 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados
BR112016025396A2 (pt) derivados de heterociclil-butanamida
CO2019001871A2 (es) Derivados de imidazol y su uso en el tratamiento de enfermedades autoinmunes o inflamatorias o cánceres.
MY155101A (en) Polyester-based fiber for artificial hair and hair ornament product including the same
AR086196A1 (es) Derivados de pirazolo[3,4-c]quinolina, inhibidores de quinasa
CO6592046A2 (es) 5-alquinil pirimidas y su uso como inhibidores de quinasa
CO6460760A2 (es) Tia-triaza-ciclopentazulenos
ECSP15021681A (es) Derivados tricíclicos fusionados de tiofeno como inhibidores de jak